Wise L David, Hoberman Alan M, Bowman Christopher J, Lewis Elise M
Independent Teratologist, Retired, Philadelphia, Pennsylvania, USA.
Consultant Developmental Toxicologist, Argus International Inc., Horsham, Pennsylvania, USA.
Birth Defects Res. 2025 May;117(5):e2479. doi: 10.1002/bdr2.2479.
The use of virtual control groups (VCGs) in nonclinical toxicology studies was first proposed in 2020 with the main purpose of reducing animal use while integrating historical control data (HCD) to enhance study interpretation. The use of VCGs has gained increasing attention as evidenced by an increasing number of publications that highlight implementation challenges. Laboratories that conduct harmonized studies with standardized procedures, consistent environmental conditions, and validated electronic databases are well-suited to implement VCGs in future nonclinical safety studies. We suggest that individual laboratories conducting rodent and rabbit developmental and reproductive toxicity studies should begin planning for VCG implementation. If possible, a harmonized approach to VCG implementation by multiple laboratories will lend credence to regulatory approval. We apply the six-step VCG implementation framework from Palazzi et al. to the routine GLP studies covered by international guidelines, which emphasize validation through retrospective and prospective trials. We discuss the risks and challenges to VCG implementation that have been previously presented. To address some of these concerns, a hybrid approach is proposed that combines a small concurrent control group (CCG) with multiple virtual control (VC) animals from the same test facility. The inclusion of a CCG addresses the need to monitor for disease and environmental changes and prevent depletion of HCD. Two approaches to the selection of VC animals are discussed. Given that developmental and reproductive toxicity studies use the most animals in nonclinical safety studies, we support the timely implementation of VCGs to significantly reduce these animal numbers.
虚拟对照组(VCG)在非临床毒理学研究中的应用于2020年首次提出,其主要目的是减少动物使用量,同时整合历史对照数据(HCD)以加强研究解读。越来越多的出版物强调了实施挑战,这表明VCG的应用受到了越来越多的关注。采用标准化程序、一致的环境条件和经过验证的电子数据库进行协调研究的实验室非常适合在未来的非临床安全性研究中实施VCG。我们建议,进行啮齿动物和兔子发育及生殖毒性研究的各个实验室应开始规划VCG的实施。如果可能的话,多个实验室采用统一的VCG实施方法将有助于获得监管批准。我们将Palazzi等人提出的六步VCG实施框架应用于国际指南涵盖的常规GLP研究,这些研究强调通过回顾性和前瞻性试验进行验证。我们讨论了此前提出的VCG实施的风险和挑战。为了解决其中一些问题,我们提出了一种混合方法,即将一个小型同期对照组(CCG)与来自同一测试机构的多只虚拟对照(VC)动物相结合。纳入CCG满足了监测疾病和环境变化以及防止HCD耗尽的需求。我们讨论了两种选择VC动物的方法。鉴于发育和生殖毒性研究在非临床安全性研究中使用的动物最多,我们支持及时实施VCG以大幅减少这些动物的数量。